A study conducted by Vasanthakumar suggested that using beta-blockers could offer several benefits to treat COVID-19, such as the reduction of the SARS-CoV-2 cell entry via downregulation of the angiotensin-converting enzyme 2 (ACE-2), reducing the expression of proinflammatory cytokines, and the reduction of complications, such as pulmonary embolism, ARDS, and septic shock [17]. This evidence concerns the gene ACE2 and pulmonary embolism.